Limits added to Zelnorm in the U.S.

04/2/2008 | Reuters

The FDA and Novartis AG announced that Zelnorm, a treatment for irritable bowel syndrome, will be restricted to patients requiring hospitalization or with life-threatening conditions. The agency said the Swiss drugmaker voluntarily decided to further limit use of the drug, which has been available only through a special FDA-supervised program since last year after clinical-trial data linked it to heart risk.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL